The invention disclosed concerns a synergistic antibody composition which produces an enhanced immunosuppressive effect, the composition containing (a) at least one monoclonal anti-CD4 antibody which, by itself, has a strong inhibitory action and (b) at least one monoclonal anti-IL2R alpha or anti-IL2R beta antibody which, by itself, has a strong inhibitory action. The invention also concerns a drug based on this antibody composition.
展开▼
